Gossamer Bio Completes Enrollment for Phase 3 PROSERA Study of PAH Drug Seralutinib

Gossamer Bio Inc. (NASDAQ:GOSS) is one of the best biotech stocks to invest in now. On June 16, Gossamer Bio announced the completion of enrollment for its global registrational Phase 3 PROSERA Study. The study is evaluating seralutinib in patients with Functional Class II and III PAH. Seralutinib is being jointly developed by Gossamer Bio and the Chiesi Group under a global collaboration agreement.

Enrollment for the PROSERA study officially closed on June 11. The study is a double-blind, placebo-controlled clinical trial designed to assess seralutinib’s efficacy when administered in addition to standard PAH therapy. Patients in the trial are randomly assigned in a 1:1 ratio to either the seralutinib or placebo groups and will receive blinded treatment for up to 48 weeks.

Gossamer Bio Completes Enrollment for Phase 3 PROSERA Study of PAH Drug Seralutinib

A hand holding up a glass vial containing a biopharmaceutical therapy.

The primary endpoint for the PROSERA Study is the change in six-minute walk distance (6MWD) from baseline compared to placebo at Week 24. Key secondary endpoints include time to clinical worsening, as compared to placebo, up to Week 48, along with other secondary and exploratory endpoints, and an evaluation of safety and tolerability. Topline results from the Phase 3 PROSERA Study are anticipated in February 2026.

Gossamer Bio Inc. (NASDAQ:GOSS) is a clinical-stage biopharmaceutical company that develops and commercializes seralutinib for the treatment of pulmonary arterial hypertension/PAH in the US. Chiesi Farmaceutici is a pharmaceutical firm that researches, develops, produces, and markets medicines for respiratory, neonatology, rare diseases, and special care therapeutic areas.

While we acknowledge the potential of GOSS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.